AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Hematopoietic Stem Cell TransplantationTransplantation, HomologousLiver TransplantationStem Cell TransplantationTransplantation, AutologousKidney TransplantationBone Marrow TransplantationTransplantation ConditioningHeart TransplantationLung TransplantationGraft vs Host DiseasePeripheral Blood Stem Cell TransplantationCell TransplantationGraft SurvivalTissue DonorsTransplantation ChimeraOrgan TransplantationGraft RejectionIslets of Langerhans TransplantationTreatment OutcomeCord Blood Stem Cell TransplantationTransplantation ImmunologyHematologic NeoplasmsPancreas TransplantationTransplantationImmunosuppressive AgentsHistocompatibility TestingTransplantation, IsogeneicRetrospective StudiesLiving DonorsRecurrenceMesenchymal Stem Cell TransplantationWhole-Body IrradiationHistocompatibilityMyeloablative AgonistsTime FactorsTransplantation, HeterotopicBusulfanHeart-Lung TransplantationImmunosuppressionTransplantation ToleranceTissue and Organ ProcurementSurvival AnalysisSurvival RateCombined Modality TherapyFetal Tissue TransplantationRemission InductionLiver FailureFollow-Up StudiesMultiple MyelomaLeukemiaMelphalanPostoperative ComplicationsCyclosporineTransplantation, HeterologousHLA AntigensGraft vs Leukemia EffectSkin TransplantationDisease-Free SurvivalTacrolimusDonor SelectionVidarabineCyclophosphamideWaiting ListsAntilymphocyte SerumCorneal TransplantationTissue TransplantationChimerismGraft vs Tumor EffectLeukemia, Myeloid, AcuteUnrelated DonorsHepatic Veno-Occlusive DiseaseCytomegalovirus InfectionsHematopoietic Stem Cell MobilizationAntineoplastic Combined Chemotherapy ProtocolsBrain Tissue TransplantationLymphocyte TransfusionAnemia, AplasticAcute DiseaseSalvage TherapySiblingsPrognosisLymphoma, Non-HodgkinHematologic DiseasesRisk FactorsMyelodysplastic SyndromesCadaverLiver DiseasesHematopoietic Stem CellsAntigens, CD34Lymphocyte DepletionPrecursor Cell Lymphoblastic Leukemia-LymphomaFacial TransplantationT-LymphocytesBronchiolitis ObliteransBlood Group IncompatibilityLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTransplantsProspective StudiesOrgan Preservation
AutologousRadiationEthicalPatients
Autologous3
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • Worldwide, approximately 90,000 first HSCTs-53% autologous and 47% allogeneic-are performed every year, according to the World Wide Network of Blood and Marrow Transplantation. (medscape.com)
Radiation1
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
Ethical2
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • Although only two years have passed since the enactment of the law, there is evidence that conditions have significantly improved, raising hopes for ethical and safe organ transplantation in Pakistan. (who.int)
Patients1